Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine + Lomustine in Recurrent Anaplastic Astrocytoma
NCT02796261Phase 3Unknown
- Sponsor
- Orbus Therapeutics
- Start
- Jul 2016
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of eflornithine in anaplastic astrocytoma (AA), sponsored by Orbus Therapeutics. Status: unknown.
02
Drugs
eflornithine
03
Conditions
anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT02796261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02796261.